Markers of oxidative/nitrative damage of plasma proteins correlated with EDSS and BDI scores in patients with secondary progressive multiple sclerosis

References

• Fitzner D, Simons M. Chronic progressive multiple sclerosis – pathogenesis of neurodegeneration and therapeutic strategies. Curr Neuropharmacol. 2010;8(3):305–315. doi: 10.2174/157015910792246218
   PubMed Web of Science ®Google Scholar
• Lassmann H, van Horssen J. The molecular basis of neurodegeneration in multiple sclerosis. FEBS Lett. 2011;585:3715–3723. doi: 10.1016/j.febslet.2011.08.004
   PubMed Web of Science ®Google Scholar
• Miljković D, Spasojević I. Multiple sclerosis: molecular mechanisms and therapeutic opportunities. Antioxid Redox Signal. 2013;19(18):2286–2334. doi: 10.1089/ars.2012.5068
   PubMed Web of Science ®Google Scholar
• Miller E. Multiple sclerosis. Adv Exp Med Biol. 2012;724:222–238. doi: 10.1007/978-1-4614-0653-2_17
   PubMed Web of Science ®Google Scholar
• Lublin FD. New multiple sclerosis phenotypic classification. Eur Neurol. 2014;72:1–5. doi: 10.1159/000367614
   PubMed Web of Science ®Google Scholar
• Miller E. Multiple sclerosis. In: Ahmad SI, editor. Neurodegenerative diseases. Springer Lands Bioscience; 2011.
   Google Scholar
• Jongen PJ, Heerings M, Lemmens WA, et al. A prospective web-based patient-centred interactive study of long-term disabilities, disabilities perception and health-related quality of life in patients with multiple sclerosis in The Netherlands: the Dutch Multiple Sclerosis Study protocol. BMC Neurol. 2015;15:1. doi: 10.1186/s12883-015-0379-0
   PubMed Web of Science ®Google Scholar
• Gandhi R, Laroni A, Weiner HL. Role of the innate immune system in the pathogenesis of multiple sclerosis. J Neuroimmunol. 2010;221(1–2):7–14. doi: 10.1016/j.jneuroim.2009.10.015
   PubMed Web of Science ®Google Scholar
• Wu GF, Alvarez E. The immuno-pathophysiology of multiple sclerosis. Neurol Clin. 2011;2:257–278. doi: 10.1016/j.ncl.2010.12.009
   Web of Science ®Google Scholar
• Desai RA, Davies AL, Tachrount M, et al. Cause and prevention of demyelination in a model multiple sclerosis lesion. Ann Neurol. 2016;79(4):591–604. doi: 10.1002/ana.24607
   PubMed Web of Science ®Google Scholar
• Najafi S, Mirshafiey A. The effect of activated microglia in progression of multiple sclerosis. Int Trends Immun. 2015;4:96–104.
   Google Scholar
• Gironi M, Borgiani B, Mariani E, et al. Oxidative stress is differentially present in multiple sclerosis courses, early evident, and unrelated to treatment. J Immunol Res. 2014;2014:1–9. doi: 10.1155/2014/961863
   Web of Science ®Google Scholar
• Karlík M, Valkovič P, Hančinová V, et al. Markers of oxidative stress in plasma and saliva in patients with multiple sclerosis. Clin Biochem. 2015;48(1–2):24–28. doi: 10.1016/j.clinbiochem.2014.09.023
   PubMed Web of Science ®Google Scholar
• Haider L, Fischer MT, Frischer JM, et al. Oxidative damage in multiple sclerosis lesions. Brain. 2011;134(7):1914–1924. doi: 10.1093/brain/awr128
   PubMed Web of Science ®Google Scholar
• Miller E, Walczak A, Saluk J, et al. Oxidative modification of patient's plasma proteins and its role in pathogenesis of multiple sclerosis. Clin Biochem. 2012;45(1–2):26–30. doi: 10.1016/j.clinbiochem.2011.09.021
   PubMed Web of Science ®Google Scholar
• Miller E, Wachowicz B, Majsterek I. Advances in antioxidative therapy of multiple sclerosis. Curr Med Chem. 2013;20(37):4720–4730. doi: 10.2174/09298673113209990156
   PubMed Web of Science ®Google Scholar
• Gilgun-Sherki Y, Melamed E, Offen D. The role of oxidative stress in the pathogenesis of multiple sclerosis: the need for effective antioxidant therapy. J Neurol. 2004;3:261–268.
   Google Scholar
• Popa-Wagner A, Mitran S, Sivanesan S, et al. ROS and brain diseases: the good, the bad, and the ugly. Oxid Med Cell Longev. 2013;2013:1–14. doi: 10.1155/2013/963520
   Web of Science ®Google Scholar
• Gutowicz M. The influence of reactive oxygen species on the central nervous system. Postep Hig Med Dos. 2011;65:104–113. doi: 10.5604/17322693.933486
   Web of Science ®Google Scholar
• Singh N, Haldar S, Tripathi AK, et al. Brain iron homeostasis: from molecular mechanisms to clinical significance and therapeutic opportunities. Antioxid Redox Signal. 2014;20(8):1324–1363. doi: 10.1089/ars.2012.4931
   PubMed Web of Science ®Google Scholar
• Jiang S, Wu J, Yang Y, et al. Proteomic analysis of the cerebrospinal fluid in multiple sclerosis and neuromyelitis optica patients. Mol Med Rep. 2012;5:1081–1086.
   Web of Science ®Google Scholar
• Pavelek B, Vyšata O, Tambor V, et al. Proteomic analysis of cerebrospinal fluid for relapsing-remitting multiple sclerosis and clinically isolated syndrome. Biomed Rep. 2016;1:35–40.
   Web of Science ®Google Scholar
• Teunissen CE, Koel-Simmelink MJ, Pham TV, et al. Identification of biomarkers for diagnosis and progression of MS by MALDI-TOF mass spectrometry. Mult Scler J. 2011;17(7):838–850. doi: 10.1177/1352458511399614
   PubMed Web of Science ®Google Scholar
• Podbielska M, Levery SB, Hogan EL. The structural and functional role of myelin fast-migrating cerebrosides: pathological importance in multiple sclerosis. Clin Lipidol. 2011;6(2):159–179. doi: 10.2217/clp.11.8
   PubMed Web of Science ®Google Scholar
• Rommer PS, Greilberger J, Salhofer-Polanyi S, et al. Elevated levels of carbonyl proteins in cerebrospinal fluid of patients with neurodegenerative diseases. Tohoku J Exp Med. 2014;234(4):313–317. doi: 10.1620/tjem.234.313
   PubMed Web of Science ®Google Scholar
• Adamczyk B, Adamczyk-Sowa M. New iinsights into the role of oxidative stress mechanisms in the pathophysiology and treatment of multiple sclerosis. Oxid Med Cell Longev. 2016;2016:1–18. doi: 10.1155/2016/1973834
   Web of Science ®Google Scholar
• Palmer AM. Multiple sclerosis and the blood-central nervous system barrier. Cardiovasc Psychiatry Neurol. 2013;2013:1–10. doi: 10.1155/2013/530356
   Google Scholar
• Hernández-Pedro NY, Espinosa-Ramirez G, de la Cruz VP, et al. Initial immunopathogenesis of multiple sclerosis: innate immune response. Clin Dev Immunol. 2013;2013:1–15. doi: 10.1155/2013/413465
   Google Scholar
• Frijhoff J, Winyard PG, Zarkovic N, et al. Clinical relevance of biomarkers of oxidative stress. Antioxid Redox Signal. 2015;23(14):1144–1170. doi: 10.1089/ars.2015.6317
   PubMed Web of Science ®Google Scholar
• Polman CH, Reingold SC, Banwell B, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol. 2011;69(2):292–302. doi: 10.1002/ana.22366
   PubMed Web of Science ®Google Scholar
• Lubin FD, Reingold SC. Defining the clinical course of multiple sclerosis results of an international survey. National Multiple Sclerosis Society USA Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology. 1996;46(4):907–911. doi: 10.1212/WNL.46.4.907
   PubMed Web of Science ®Google Scholar
• Beck AT, Epstein N, Brown G, et al. An inventory for measuring clinical anxiety: psychometric properties. J Consult Clin Psychol. 1988;56(6):893–897. doi: 10.1037/0022-006X.56.6.893
   PubMed Web of Science ®Google Scholar
• Buss H, Chan TP, Sluis KB, et al. Protein carbonyl measurement by a sensitive ELISA method. Free Rad Biol Med. 1997;23(3):361–366. doi: 10.1016/S0891-5849(97)00104-4
   PubMed Web of Science ®Google Scholar
• Alamdari DH, Kostidou E, Paletas K, et al. High sensitivity enzyme-linked immunosorbent assay (ELISA) method for measuring protein carbonyl in samples with low amounts of protein. Free Radic Biol Med. 2005;39(10):1362–1367. doi: 10.1016/j.freeradbiomed.2005.06.023
   PubMed Web of Science ®Google Scholar
• Levine RL, Garland D, Oliver CN, et al. Determination of carbonyl content in oxidatively modified proteins. Method Enzymol. 1990;186:464–478. doi: 10.1016/0076-6879(90)86141-H
   PubMed Web of Science ®Google Scholar
• Placer ZA, Cushman LL, Johnson BC. Estimation of product of lipid peroxidation (malonyldialdehyde) in biochemical systems. Anal Biochem. 1966;16(2):359–364. doi: 10.1016/0003-2697(66)90167-9
   PubMed Web of Science ®Google Scholar
• Khan J, Brennan DM, Bradley N, et al. 3-nitrotyrosine in the proteins of human plasma determined by an Elisa method. Biochem J. 1998;330(2):795–801. doi: 10.1042/bj3300795
   PubMed Web of Science ®Google Scholar
• Ellman GL. Tissue sulfhydryl groups. Arch Biochem Biophys. 1959;82(1):70–77. doi: 10.1016/0003-9861(59)90090-6
   PubMed Web of Science ®Google Scholar
• Hu ML. Measurement of protein thiol groups and glutathione in plasma. Method Enzymol. 1994;233:380–385. doi: 10.1016/S0076-6879(94)33044-1
   PubMed Web of Science ®Google Scholar
• Koster JF, Biemond P, Swaak AJ. Intracellular and extracellular sulphydryl levels in rheumatoid arthritis. Ann Rheum Dis. 1986;45(1):44–46. doi: 10.1136/ard.45.1.44
   PubMed Web of Science ®Google Scholar
• Hauke J, Kossowski T. Comparison of values of Pearson’s and Spearman’s correlation coefficients on the same sets of data. Quaest Geogr. 2011;2:87–93.
   Google Scholar
• Trapp BD, Nave KA. Multiple sclerosis: an immune or neurodegenerative disorder? Annu Rev Neurosci. 2008;31:247–269. doi: 10.1146/annurev.neuro.30.051606.094313
   PubMed Web of Science ®Google Scholar
• Koch M, Ramsaransing GS, Arutjunyan AV, et al. Oxidative stress in serum and peripheral blood leukocytes in patients with different disease courses of multiple sclerosis. J Neurol. 2006;253(4):483–487. doi: 10.1007/s00415-005-0037-3
   PubMed Web of Science ®Google Scholar
• Stoop MP, Singh V, Dekker LJ, et al. Proteomics comparison of cerebrospinal fluid of relapsing remitting and primary progressive multiple sclerosis. PLoS One. 2010;5(8):e12442. doi: 10.1371/journal.pone.0012442
   PubMed Web of Science ®Google Scholar
• Lukáč Š, Kalnovičová T, Muchová J. Evaluation of oxidative and nitrosative stress in relapsing remitting multiple sclerosis. Health. 2013;05(11):1924–1928. doi: 10.4236/health.2013.511260
   Google Scholar
• Miller E, Mrowicka M, Malinowska K, et al. Effects of whole-body cryotherapy on a total antioxidative status and activities of antioxidative enzymes in blood of depressive multiple sclerosis patients. World J Biol Psychiatry. 2011;12(3):223–227. doi: 10.3109/15622975.2010.518626
   PubMed Web of Science ®Google Scholar
• Miller E, Mrowicka M, Malinowska K, et al. The effects of whole-body cryotherapy and melatonin supplementation on total antioxidative status and some antioxidative enzymes in multiple sclerosis patients. Pol Merkur Lekarski. 2011;31(183):150–153.
   PubMedGoogle Scholar
• Fiorini A, Koudriavtseva T, Bucaj E, et al. Involvement of oxidative stress in occurrence of relapses in multiple sclerosis: the spectrum of oxidatively modified serum proteins detected by proteomics and redox proteomics analysis. PLoS One. 2013;8(6):e65184. doi: 10.1371/journal.pone.0065184
   PubMed Web of Science ®Google Scholar
• Mao P, Reddy PH. Is multiple sclerosis a mitochondrial disease? Biochim Biophys Acta. 2010;1802(1):66–79. doi: 10.1016/j.bbadis.2009.07.002
   PubMed Web of Science ®Google Scholar
• Morel A, Bijak M, Miller E, et al. Relationship between the increased haemostatic properties of blood platelets and oxidative stress level in multiple sclerosis patients with the secondary progressive stage. Oxid Med Cell Longev. 2015;2015:1–10. doi: 10.1155/2015/240918
   Web of Science ®Google Scholar
• Tseng CH, Huang WS, Lin CL, et al. Increased risk of ischaemic stroke among patients with multiple sclerosis. Eur J Neurol. 2015;22:500–506. doi: 10.1111/ene.12598
   PubMed Web of Science ®Google Scholar
• Liu S, Bai S, Qin Z, et al. Quantitative proteomic analysis of the cerebrospinal fluid of patients with multiple sclerosis. J Cell Mol Med. 2009;13:1586–1603. doi: 10.1111/j.1582-4934.2009.00850.x
   PubMed Web of Science ®Google Scholar
• Ottervald J, Franzén B, Nilsson K, et al. Multiple sclerosis: identification and clinical evaluation of novel CSF biomarkers. J Proteomics. 2010;73(6):1117–1132. doi: 10.1016/j.jprot.2010.01.004
   PubMed Web of Science ®Google Scholar
• Mancall EL, Brock DG. Clinical nauroanatomy. The anatomic basis for clinical neuroscience. Philadelphia; 2011: p. 1–11.
   Google Scholar
• Cristalli DO, Arnal N, Marra FA, et al. Peripheral markers in neurodegenerative patients and their first-degree relatives. J Neurol Sci. 2012;314(1–2):48–56. doi: 10.1016/j.jns.2011.11.001
   PubMed Web of Science ®Google Scholar
• Sinem F, Dildar K, Gökhan E, et al. The serum protein and lipid oxidation marker levels in Alzheimer’s disease and effects of cholinesterase inhibitors and antipsychotic drugs therapy. Curr Alzheimer Res. 2010;7(5):463–469. doi: 10.2174/156720510791383822
   PubMed Web of Science ®Google Scholar
• Torres LL, Quaglio NB, De Souza GT, et al. Peripheral oxidative stress biomarkers in mild cognitive impairment and Alzheimer’s disease. J Alzheimers Dis. 2011;26(1):59–68.
   PubMed Web of Science ®Google Scholar
• Nikolova GD, Grigorov BG, Zheleva AM, et al. Influence of therapy on some important final products of oxidation of lipids, proteins and nucleic acids in patients with Parkinson’s Diseases. Biol Chem. 2014;4:253–260.
   Google Scholar
• Olas B, Wachowicz B. Role of reactive nitrogen species in blood platelet functions. Platelets. 2007;18(8):555–565. doi: 10.1080/09537100701504087
   PubMed Web of Science ®Google Scholar
• Bolton C, Wood EG, Scott GS, et al. A comparative evaluation of the response to peroxynitrite by a brain endothelial cell line and control of the effects by drug targeting. Cell Mol Neurobiol. 2009;29(5):707–717. doi: 10.1007/s10571-009-9391-5
   PubMed Web of Science ®Google Scholar
• Wachowicz B. Blood platelets as a peripheral cell in oxidative stress in psychiatric disorders. In: Dietrich-Muszalska A, Chauhan V, Grignon S, editors. Studies on psychiatric disorders. New York (NJ): 2015. p. 327–353.
   Google Scholar
• Yuceyar N, Taşkiran D, Sağduyu A. Serum and cerebrospinal fluid nitrite and nitrate levels in relapsing-remitting and secondary progressive multiple sclerosis patients. Clin Neurol Neurosurg. 2001;103(4):206–211. doi: 10.1016/S0303-8467(01)00144-5
   PubMed Web of Science ®Google Scholar
• Wang P, Xie K, Wang C, et al. Oxidative stress induced by lipid peroxidation is related with inflammation of demyelination and neurodegeneration in multiple sclerosis. Eur Neurol. 2014;72(3-4):249–254. doi: 10.1159/000363515
   PubMed Web of Science ®Google Scholar
• Koch M, Mostert J, Arutjunyan AV, et al. Plasma lipid peroxidation and progression of disability in multiple sclerosis. Eur J Neurol. 2007;14(5):529–533. doi: 10.1111/j.1468-1331.2007.01739.x
   PubMed Web of Science ®Google Scholar
• Hadžović-Džuvo A, Lepara O, Valjevac A, et al. Serum total antioxidant capacity in patients with multiple sclerosis. Bosn J Basic Med Sci. 2011;11(1):33–36.
   PubMed Web of Science ®Google Scholar
• Oliveira SR, Kallaur AP, Simão AN, et al. Oxidative stress in multiple sclerosis patients in clinical remission: association with the expanded disability status scale. J Neurol Sci. 2012;321(1–2):49–53. doi: 10.1016/j.jns.2012.07.045
   PubMed Web of Science ®Google Scholar